

S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Timothy L. Macdonald

Examiner: Unknown

Serial No.: Unknown

Group Art Unit: Unknown

Filed: Herewith

Docket: 1036.031US3

Title: FELBAMATE DERIVED COMPOUNDS

PRELIMINARY AMENDMENT


Commissioner for Patents
Washington, D.C. 20231

Before taking up the above-identified application for examination, please amend it as follows.

IN THE CLAIMS

Please substitute the below claim set for the previously pending claim set. The below claim set is intended to reflect cancellation of claims 1-30, and the addition of new claims 31-45.

31.(NEW) A compound of the formula:



wherein: R₂ is halo; and R₃ is hydroxy or -OCONH₂.

32.(NEW) The compound of claim 31 wherein R₂ is chloro or fluoro.

33.(NEW) The compound of claim 31 wherein R₂ is fluoro.

34.(NEW) The compound of claim 31 wherein R₃ is hydroxy.

35.(NEW) The compound of claim 31 wherein R₃ is -OCONH₂.

- 36.(NEW) The compound of claim 34 wherein R₂ is chloro or fluoro.
- 37.(NEW) The compound of claim 34 wherein R₂ is fluoro.
- 38.(NEW) The compound of claim 35 wherein R₂ is chloro or fluoro.
- 39.(NEW) The compound of claim 35 wherein R₂ is fluoro.
- 40.(NEW) A composition comprising a compound as described in claim 31, and a pharmaceutically acceptable carrier.
41. (NEW) A composition comprising a compound as described in claim 39, and a pharmaceutically acceptable carrier.
- 42.(NEW) A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 31.
- 43.(NEW) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising administering to the patient, an effective amount of a compound as described in claim 31.
- 44.(NEW) A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 39.
- 45.(NEW) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising administering to the patient, an effective amount of a compound as described in claim 39.

PRELIMINARY AMENDMENT

Serial Number: Unknown

Filing Date: Herewith

Title: FELBAMATE DERIVED COMPOUNDS

Page 3

Dkt: 1036.031US3

REMARKS

Claims 1-30 have been canceled and replaced with claims 31-45. Applicant reserves the right to pursue the canceled subject matter in subsequent continuing applications. The amendments made herein were not made for reasons relating to patentability; they were made to facilitate prosecution. Thus, the pending claims are entitled to a full scope of equivalents.

Respectfully submitted,

TIMOTHY L. MACDONALD

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3265

Date 12-17-01 By 

Robert J. Harris, Ph.D.
Reg. No. 37,346

"Express Mail" mailing label number: EL873859035US

Date of Deposit: December 17, 2001

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to The Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.